416 results on '"Copelan, Edward A."'
Search Results
2. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
3. Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy
4. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
5. Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
6. COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients
7. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
8. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients
9. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
10. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation
11. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
12. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes
13. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS
14. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
15. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
16. Survival following allogeneic transplant in patients with myelofibrosis
17. Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries
18. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
19. A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant
20. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades
21. Allogeneic hematopoietic cell transplantation; the current renaissance
22. Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
23. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis
24. Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation
25. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia
26. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
27. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials
28. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
29. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
30. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia
31. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma
32. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation
33. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study
34. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
35. Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics
36. Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer
37. Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation
38. Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Lingering Uncertainties and Emerging Possibilities
39. Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
40. Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation
41. Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study
42. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI
43. Providing Personalized Prognostic Information for Adult Leukemia Survivors
44. Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax
45. Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research
46. Defining Incidence, Risk Factors, and Impact on Survival of Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome
47. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
48. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes
49. Risk Factors for 30-Day Hospital Readmission following Myeloablative Allogeneic Hematopoietic Cell Transplantation (allo-HCT)
50. Acquired Immunity in Patients with Multiple Myeloma Undergoing Maintenance Therapy Post-Autologous Hematopoietic Cell Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.